/
PLRX
$1.15+$0.01 (+0.88%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$70.6M
62M shares
52-week range
$1.09 – $1.95
7% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.29%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-27.83
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $57.1M | $41.8M | $7.6M | $9.7M | $1.6M | $0 | $0 |
| Cost of revenue | $666.0K | $0 | $0 | $0 | $0 | $0 | $0 | $1.7M |
| Gross profit | −$666.0K | $57.1M | $41.8M | $7.6M | $9.7M | $1.6M | $0 | −$1.7M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| R&D | $24.4M | $47.4M | $66.2M | $77.5M | $96.9M | $127.8M | $169.3M | $109.2M |
| Operating income | −$30.9M | −$1.2M | −$41.6M | −$97.5M | −$127.2M | −$184.1M | −$228.4M | −$150.1M |
| EBITDA | −$30.2M | −$118.0K | −$40.3M | −$95.7M | −$118.8M | −$158.2M | −$205.2M | −$145.1M |
| Net income | −$30.3M | −$631.0K | −$41.5M | −$97.3M | −$123.3M | −$161.3M | −$210.3M | −$149.3M |
| Net margin | — | -1.1% | -99.3% | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (diluted) | -1.83 | 0.01 | -1.17 | -2.71 | -2.94 | -2.75 | -3.47 | -2.43 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-1.41 | $-1.52–$-1.33 | 4 |
| 2027 | $5M | $-1.05 | $-1.13–$-0.92 | 4 |
| 2028 | $15M | $-0.95 | $-1.49–$-0.28 | 4 |
| 2029 | $15M | $-1.08 | $-1.08–$-1.08 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.27
Price
$1.15
Implied downside
-76%
Peer comparison
Pliant Therapeutics, Inc. Common Stock
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
www.pliantrx.com- Employees
- 49
- IPO / List date
- Jun 3, 2020
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds PLRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,852,842 | $2.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PLRX yet.
